Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products in the healthcare field. The company operates through three business segments, including Consumer; Pharmaceutical and Medical Devices; and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women's Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. These products are marketed principally to the general public and sold both to wholesalers and directly to independent and chain retail outlets throughout the world. Pharmaceutical The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use by the general public. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX (topiramate), approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT (Epoetin alfa, sold outside the U.S. as EPREX), a biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral (risperidone), a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients, RISPERDAL CONSTA (risperidone), a long-acting injectable, and INVEGA (paliperdone) Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN (levofloxacin) and FLOXIN (ofloxacin), both in the anti-infective field; CONCERTA (methylphenidate HCl), a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal (fentanyl transdermal system, sold outside the U.S. as DUROGESIC), a treatment for chronic pain that offers a novel delivery system. Medical Devices and Diagnostics The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis' circulatory disease management products; DePuy's orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon's surgical care and women's health products; Ethicon Endo-Surgery's minimally invasive surgical products; LifeScan's blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics' professional diagnostic products and Vistakon's disposable contact lenses.

Research Grants 215 show all


$120.5M
2015

$105.6M
2016

$137.9M
2017

$214.7M
2018

$143.7M
2019

Publications 28 show all

  • 2
    Piperazines/pharmacology
  • 2
    Piperidines/analysis
  • 2
    Piperidines/pharmacokinetics
  • 1
    Adenosine Deaminase/pharmacology
  • 1
    Adenosine/pharmacology
  • 1
    Anticonvulsants/pharmacology
  • 1
    Antifungal Agents/pharmacology
  • 1
    Bile/analysis
  • 1
    Candida/drug effects
  • 1
    Cell Movement

Patents 81,736show all

  • 12,644
    A61K - Preparations for medical, dental, or toilet purposes
  • 8,941
    C07D - Heterocyclic compounds
  • 5,721
    A61B - Diagnosis
  • 4,956
    A61F - Filters implantable into blood vessels
  • 2,848
    G02C - Spectacles
  • 2,528
    A61Q - Specific use of cosmetics or similar toilet preparations
  • 2,401
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 2,169
    A61M - Devices for introducing media into, or onto, the body
  • 2,151
    B29D - Producing particular articles from plastics or from substances in a plastic state
  • 2,099
    A61L - Methods or apparatus for sterilising materials or objects in general

Clinical Trials 1,720show all

465Phase 3342N/A311Phase 2237Phase 1126Phase 457Other

SEC Filings show all


230
8-K

81
10-Q

22
10-K

Contact Information

One Johnson & Johnson Plaza
New Brunswick, NJ 08933
United States

Overview

Total FundingEmployeesLast Funding DateStatus
10000+Ipo